Medication info

Baotan Tablet 160mg (Valsartan)

Prescription medicationTabletOralExpired
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Korea Nelson Pharmaceutical Co., Ltd.
Appearance
Oval film-coated tablet with an orange color and a gray tint
Packaging
100 tablets (bottle), 30 tablets (bottle)
Approval status
Expired

MFDS item code 201310742 · Approved 2013.12.17

This product's status changed to Expired on 2023.12.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect occurs gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with fluid depletion: For patients with fluid depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily, which may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily; over the following several weeks, increase the dose as tolerated to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or more. However, as there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: The daily dose of this drug should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Ingredients

Manufacturer
Korea Nelson Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used in the treatment of essential hypertension. It is also effective for patients with heart failure who are intolerant to ACE inhibitors and belong to NYHA class II to IV. It helps reduce the risk of death in stable patients with left ventricular failure or left ventricular systolic dysfunction after myocardial infarction. Therefore, it plays an important role not only in treating hypertension and heart failure but also in preventive management after myocardial infarction. This drug is used to improve cardiovascular health and protect life.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect occurs gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with fluid depletion: For patients with fluid depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily, which may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily; over the following several weeks, increase the dose as tolerated to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or more. However, as there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: The daily dose of this drug should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. It is safe for pregnant women or those who may become pregnant and for breastfeeding women to avoid this medication. Patients with severely impaired liver function, very poor kidney function, or a history of certain vascular edema should also not use this medication. The elderly, patients with hyperkalemia, and those with mild to moderate liver impairment should use this medication cautiously and should start with low doses that are gradually increased. This drug has a blood pressure-lowering effect and can cause dizziness or fainting due to sudden blood pressure drops upon initial use. Patients undergoing dialysis or taking diuretics and patients with strict sodium restrictions are at higher risk of hypotension and should be closely monitored. Blood pressure, kidney function, and serum potassium levels should be regularly checked during treatment to detect abnormalities. Additionally, caution is needed when taking potassium-sparing diuretics or potassium supplements together, as this can lead to dangerously high serum potassium levels. The efficacy of this medication can change when used with other antihypertensive medications or certain anti-inflammatory pain relievers, so consultation with a physician is recommended. Caution is necessary while driving or operating machinery due to potential dizziness. Safety for children and adolescents has not been established, so use is not recommended. In the case of an overdose, severe hypotension or loss of consciousness can occur, and immediate medical attention should be sought. This medication should be kept out of reach of children, and it is advisable to avoid transferring it to another container.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is important to keep it in a cool place below 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Oval film-coated tablet with an orange color and a gray tint

Package unit

100 tablets (bottle), 30 tablets (bottle)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.